for the long term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.
He highlighted a European analysis of six phase III clinical trials totaling more than 27,000 patients with venous thromboembolism (VTE) in which dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), or edoxaban (Savaysa) was compared to the traditional strategy of unfractionated or low-molecular-weight heparin
(LMWH) bridging to warfarin or another vitamin K antagonist.
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin
or unfractionated heparin.
The investigators were able to reproduce the rule by applying it to data from two randomized controlled trials that compared a low-molecular-weight heparin
with a vitamin K antagonist, Dr.
Houde JP, Steinberg G 1999 Intrahepatic hemorrhage after use of low-molecular-weight heparin
for total hip arthroplasty Journal of Arthroplasty 14 (3) 372-374
The authors conducted a literature search to identify randomized trials that compared unfractionated heparin with control, low-molecular-weight heparin
with control, low-molecular-weight heparin
with unfractionated heparin, or a selective factor Xa inhibitor (fondaparinux) with placebo for reducing DVT, pulmonary embolism (PE), or mortality in hospitalized medical patients.
was designed to behave more predictably in the body, thereby making monitoring unnecessary.
Location was unaffected by the use of low-molecular-weight heparin
have reached an agreement in which the latter will market Fragmin, a low-molecular-weight heparin
in the United States.
versus unfractionated heparin in the treatment of patients with acute pulmonary thromboembolism.
- An opportunity for home treatment of venous thrombosis.
In the standard therapy arm, once patients were off low-molecular-weight heparin
and on warfarin they were within the target INR 58% of the time.